Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-509 in Moderate to Severe Diabetic Neuropathy
NCT00476931Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- May 2007
- Primary completion
- Jul 2010
- Modality
- Gene Silencing, Plasmid DNA, Zinc Finger Nucleases
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in diabetic neuropathy comparing SB-509 with Placebo (2 arms). Primary endpoints: Total Neuropathy Score at 1 year, Nerve Conduction Velocity at 1 year and 3 more. Started May 2007; status: completed.
02
Drugs
SB-509
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT00476931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00476931.